Table 3.
Driver oncogene mutations stratified by PD-L1 Tumor Proportion Score (TPS) and by specimen type
| Oncogene mutation (overall cohort) | Total (n=223) | <1% PD-L1 TPS (n=87) | 1–49% PD-L1 TPS (n=55) | ≥50% PD-L1 TPS (n=81) |
|---|---|---|---|---|
| EGFR | 30 (13.5%) | 14 (16.1%) | 10 (18.2%) | 6 (7.4%) |
| ALK | 7 (3.1%) | 2 (2.3%) | 0 (0%) | 5 (6.2%) |
| ROS1 | 2 (0.9%) | 1 (1.1%) | 1 (1.8%) | 0 (0%) |
| KRAS | 60 (27.0%) | 19 (21.8%) | 13 (23.6%) | 28 (34.6%) |
| Oncogene mutation (cytology cell block) | Total (n=88) | <1% PD-L1 TPS (n=35) | 1–49% PD-L1 TPS (n=20) | ≥50% PD-L1 TPS (n=33) |
| EGFR | 12 (13.6%) | 6 (17.1%) | 5 (25.0%) | 1 (3.0%) |
| ALK | 4 (4.5%) | 1 (2.9%) | 0 (0%) | 3 (9.1%) |
| ROS1 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| KRAS | 24 (27.3%) | 9 (25.7%) | 4 (20.0%) | 11 (33.3%) |
| Oncogene mutation (surgical pathology) | Total (n=135) | <1% PD-L1 TPS (n=52) | 1–49% PD-L1 TPS (n=35) | ≥50% PD-L1 TPS (n=48) |
| EGFR | 18 (13.3%) | 8 (15.4%) | 5 (14.3%) | 5 (10.4%) |
| ALK | 3 (2.2%) | 1 (1.9%) | 0 (0%) | 2 (4.2%) |
| ROS1 | 2 (1.5%) | 1 (1.9%) | 1 (2.9%) | 0 (0%) |
| KRAS | 36 (26.7%) | 10 (19.2%) | 9 (25.7%) | 17 (35.4%) |
Statistical comparisons for cytology cell block vs. surgical pathology specimens: total, p = 0.62; <1% PD-L1 TPS, p = 1.0; 1–49% PD-L1 TPS, p=0.64; ≥50% PD-L1 TPS, p=0.39; Fisher exact test.